Who is sponsoring NCT06941766?

NCT06941766 is sponsored by Peking Union Medical College Hospital.

What condition does NCT06941766 study?

NCT06941766 studies Intermediate Trophoblastic Tumor.

What drugs are being tested in NCT06941766?

Interventions: QL1706, Chemotherapy.

What is the status of NCT06941766?

NCT06941766 is currently RECRUITING.

Last reviewed 2025-04-30 · How we verify

Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors

NCT06941766 PHASE1, PHASE2 RECRUITING

This clinical trial aims to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706), a dual-targeting immunotherapy (anti-PD-1/CTLA-4), in patients with intermediate trophoblastic tumors (ITT). The main questions it aims to answer are: Does QL1706 improve complete response (CR) rates (primary endpoint) and survival outcomes? What are the safety profiles of QL1706 in ITT, including immune-related adverse events? Participants will receive QL1706 (5 mg/kg IV, Q3W) ± chemotherapy (FAEV/EMA/EP/EMA/CO/TP-TE). They will also receive Maintenance therapy post-hCG normalization. Efficacy is assessed via serial β-hCG tests, imaging (every 9-12 weeks), and biomarker analysis.

Details

Lead sponsor	Peking Union Medical College Hospital
Phase	PHASE1, PHASE2
Status	RECRUITING
Enrolment	20
Start date	Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Apr 16 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Intermediate Trophoblastic Tumor

Interventions

QL1706
Chemotherapy

Countries

China